Q&A Session: Access to Buprenorphine Treatment for Opioid Use Disorder

ORN Webinar Series: Q&A session following a lecture covering the current landscape of buprenorphine treatment availability and ongoing issues is making this medication available, accessible and sustainable for all in need.

Goals & Objectives: 

  1. Review the evidence around buprenorphine treatment for opioid use disorder
  2. Review epidemiology of access to buprenorphine in general population and special interest groups (e.g. justice involved, pregnant women)
  3. Discuss primary barriers to entry and retention in treatment
  4. Review effective models and solutions for expansion of buprenorphine treatment and improved linkage to this type of care, including low threshold and telemedicine models
  5. Discuss issues related to buprenorphine access during the COVID-19 pandemic

Needs Assessment: 

Will introduce audience to micro and macro issues around access to life saving opioid use disorder treatment - from stigma to policies around controlled substances. Audience will be introduced to current evidence on the success and remaining gaps in making buprenorphine accessible to those in need, including the roles of physicians in de-stigmatizing opioid use disorder and its treatment and offering this medication to patients in need.

This webinar has been approved for 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Noa Krawczyk, PhD

Noa Krawczyk is an assistant professor in the Department of population health at NYU School of Medicine and a member of the center of Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use Epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatments for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies an advancing science that can help inform evidence-based policy Zen practices that reduce harm and promote long term recovery. 

Brendan Saloner, PhD

Brendan Saloner, PhD, is an Associate Professor in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. His research focuses on the intersection between health and social policy, particularly on the role of health insurance in promoting access to care, financial protection, and wellness. Dr. Saloner has extensive research focused on the financing, organization, and delivery of mental health and substance use treatment among children, adolescents, and young adults. He is interested in the transformation of public sector behavioral health and primary care health systems under the Affordable Care Act. Dr. Saloner is also interested in applied ethical issues related to equitable health care financing and the design of health insurance.

Julie Kmiec, DO, FAOAAM (Moderator)

Julie Kmiec, DO, FAOAAM graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific. She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine. She is board certified in general and addiction psychiatry. Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program and the Narcotic Addiction Treatment Program Buprenorphine Clinic at WPIC. Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and medication assisted treatment of addictions. President of the American Osteopathic Academy of Addiction Medicine, 2019 & 2020.

Planner & Moderator for this webinar.

Key:

Complete
Failed
Available
Locked
Webinar - Q&A Session: Access to Buprenorphine Treatment for Opioid Use Disorder
03/31/2021 at 5:00 PM (EDT)   |  60 minutes
03/31/2021 at 5:00 PM (EDT)   |  60 minutes A lecture covering the current landscape of buprenorphine treatment availability and ongoing issues is making this medication available, accessible and sustainable for all in need.
Survey - Q&A Session: Access to Buprenorphine Treatment for Opioid Use Disorder
13 Questions
13 Questions SAMHSA - Requires a survey taken by attendees. Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Medical Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available